Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 5/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382931 | 1.00 | GSK3A (0.48) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL18050740 | 0.82 | GSK3A (0.51) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL9904691 | 0.81 | GSK3A (0.45) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL29382832 | 0.77 | GSK3A (0.57) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL2959525 | 0.77 | GSK3A (0.43) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL2966812 | 0.77 | GSK3A (0.43) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL29380963 | 0.77 | GSK3A (0.43) | GSK3AGSK3BPDGFRBKDRPRMT5 | |
| SCHEMBL30379604 | 0.75 | PRMT5 (0.42) | GSK3AGSK3BPRMT5WDR77EGFR | |
| SCHEMBL1519972 | 0.75 | PRMT5 (0.42) | GSK3AGSK3BPRMT5WDR77EGFR | |
| SCHEMBL1585585 | 0.74 | GSK3A (0.45) | GSK3AGSK3BPDGFRBKDRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021249913-A1 | 2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-16 | — | — | WO | disclosed |
| CN-107406462-B | Tricyclic DLK inhibitors and uses thereof | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| US-10131675-B2 | Tricyclic DLK inhibitors and uses thereof | GENENTECH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3268373-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | GSK3A 1761/4885GSK3B 1645/4885PDGFRB 4316/4885 |
| US-10131675-B2 | Tricyclic DLK inhibitors and uses thereof | NLK, DCLK2, DLK1 | GSK3A 468/4885GSK3B 445/4885PDGFRB 3189/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | GSK3A 298/4885GSK3B 168/4885PDGFRB 1145/4885 |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | NLK, DCLK2, DLK1 | GSK3A 468/4885GSK3B 445/4885PDGFRB 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.